Skip to content

Training programme in facial emotions imitation among patients with schizophrenia

Facial emotion imitation training in outpatients with schizophrenia: Demonstrating the effectiveness of facial imitation to improve the recognition of facial emotions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15190595
Enrollment
50
Registered
2017-04-26
Start date
2015-11-24
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Interventions

Participants are randomised into one of two group using a sequence of random numbers (N / 2) assigning that sequence to the intervention or random control group. Intervention group: P

Sponsors

Servicio Gallego de Salud (SERGAS)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Provision of informed consent to participate 2. Aged between 18 and 55 years old 3. Diagnosed with schizophrenia (DSM-5) 4. Clinically stable 5. Users of mental health facilities in the moment of the research 6. Treated with atypical antipsychotics

Exclusion criteria

Exclusion criteria: 1. Presence of a comorbid psychiatric or neurological disorder, intellectual disability 2. Abuse of toxic substances in the moment of the research (excluding nicotine)

Design outcomes

Secondary

MeasureTime frame
1. Symptom severity is assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and 2 months 2. Verbal and non-verbal knowledge are measured using the Intelligence Test (K-BIT) at baseline and 2 months

Primary

MeasureTime frame
Facial recognition of emotional expressions is measured using the Ekman 60 Faces Test (Ekman 60) and the Penn Emotion Recognition Task (ER-40 test) at baseline and 2 months.

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026